monjaro tirzepatide How the weight loss drug is also helping heart failure patients Tirzepatide (Mounjaro): Type 2 Diabetes

Suitable for use as the sole source of nutrition for infants from birth and as part of a balanced diet from 6-12 months

It can also cause low blood sugar levels in people with Type 2 diabetes, especially when used in combination with insulin or certain diabetes drugs

It also helps regulate post-meal blood sugar by coordinating insulin release and reducing glucagon production

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO [see Drug Interactions (7.2) and Clinical Pharmacology (12.2, 12.3)]

Hepatology 2006;43:173-81.ArticlePubMedPMC 37